GlassScriptPhysician profile
Ashley Barras
NPI 1811684087
$2,530.36
in general payments reported to CMS, 2019-2025
15 companies · $2,180 in 2025
The $2,180 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $350 · 2025: $2,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.38 |
| Education | $166.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $524.47 | 2024-2025 | |
| Galderma Laboratories, L.P. | $402.15 | 2024-2025 | Nemluvio |
| Ucb, INC. | $294.14 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $285.04 | 2024-2025 | |
| Janssen Biotech, INC. | $236.36 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.34 | 2024-2025 | Spevigo |
| Abbvie INC. | $150.57 | 2025 | |
| Janssen Scientific Affairs, LLC | $101.98 | 2025 | Tremfya |
| Krystal Biotech INC | $100.14 | 2025 | Vyjuvek |
| Regeneron Healthcare Solutions, INC. | $97.88 | 2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $53.42 | 2025 | |
| Organon LLC | $27.88 | 2025 | Vtama |
| Botanix Sb INC | $25.94 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $23.55 | 2025 | Sotyktu |
| Amgen INC. | $22.50 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Barras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.